Compugen Announces First Patient Dosed in Phase 1 Clinical Trial to Evaluate COM503 as Monotherapy and in Combination with Zimberelimab in Advanced Solid Tumors
Portfolio Pulse from
Compugen Ltd. has dosed the first patient in a Phase 1 clinical trial for COM503, an anti-IL-18 binding protein antibody, licensed to Gilead Sciences. The trial will evaluate COM503 as a monotherapy and in combination with Zimberelimab for advanced solid tumors.
January 08, 2025 | 12:15 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Compugen Ltd. has initiated a Phase 1 trial for COM503, a novel anti-IL-18 antibody, marking a significant step in cancer immunotherapy. The trial will assess its safety and efficacy as a monotherapy and in combination with Zimberelimab.
The initiation of a Phase 1 trial for COM503 represents a significant milestone for Compugen, potentially enhancing its pipeline and market perception. The trial's success could lead to further development and partnerships, positively impacting CGEN's stock.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 90
POSITIVE IMPACT
Gilead Sciences is involved in the development of COM503, an anti-IL-18 antibody licensed from Compugen, which is now in Phase 1 trials for cancer treatment.
Gilead's involvement in the COM503 trial could enhance its oncology portfolio. Positive trial outcomes may strengthen Gilead's position in cancer therapeutics, potentially boosting investor confidence.
CONFIDENCE 85
IMPORTANCE 60
RELEVANCE 70